Stem Cell Clinic

Telo Genomics Launches a Commercial Evaluation of Applied Spectral Imaging Automation (AI) with TELO Workflow

By Global News Feed

TORONTO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce that it has launched a commercial evaluation in collaboration with Applied Spectral Imaging (ASI) California to assess the applicability of integrating GenASIs™, the ASI automated imaging and analysis solutions into TELO’s workflow.

Read more here:
Telo Genomics Launches a Commercial Evaluation of Applied Spectral Imaging Automation (AI) with TELO Workflow

Globally Renowned Cystic Fibrosis Expert, Dr. Eitan Kerem, Joins Eloxx Pharmaceuticals as a Senior Consultant

By Global News Feed

WALTHAM, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that Professor Eitan Kerem, M.D. has joined the Company as a Senior Consultant. Dr. Kerem will continue to advise on our cystic fibrosis program focusing on strategic leadership, cystic fibrosis medical safety review, and medical communications, as well as liaising with patient advocacy groups and regulatory authorities.

Excerpt from:
Globally Renowned Cystic Fibrosis Expert, Dr. Eitan Kerem, Joins Eloxx Pharmaceuticals as a Senior Consultant

Ansun Biopharma to Present at H.C. Wainwright & Co. 22nd Annual Global Investment Conference

By Global News Feed

SAN DIEGO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Ansun Biopharma, Inc., a clinical stage biopharmaceutical company, today announced the company will present at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference, taking place September 14-16. During the conference, Nancy Chang, Ph.D., chief executive officer of Ansun, will deliver a corporate update to potential investors registered for the meeting. The corporate update will cover recent and upcoming company milestones, as well as detail clinical progress of the company’s lead drug candidate, DAS181, a multi-mechanism recombinant sialidase protein being studied for its potential to treat patients with respiratory diseases, including influenza and parainfluenza, by preventing viral entry into respiratory epithelial cells. Ansun is also assessing DAS181 in patients with severe COVID-19 in Phase 2 studies.

Read the original post:
Ansun Biopharma to Present at H.C. Wainwright & Co. 22nd Annual Global Investment Conference

NextCure Announces Appointment of John G. Houston, Ph.D., to its Board of Directors

By Global News Feed

BELTSVILLE, Md., Sept. 14, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of John G. Houston, Ph.D., to its board of directors as of September 10, 2020. Dr. Houston has more than 30 years of experience in the pharmaceutical and biotech industry and currently serves as president and chief executive officer of Arvinas, Inc. In addition, Judith Li has announced that she is stepping down from the company’s board of directors.

Go here to see the original:
NextCure Announces Appointment of John G. Houston, Ph.D., to its Board of Directors

→←